Aaron Maguregui Outlines AI Regulation and Pharma Challenges in Health Care
Foley & Lardner LLP partner Aaron Maguregui examining the regulatory landscape for AI in the health care industry in the PharmaVoice article, “As artificial intelligence increasingly takes on new patient-facing roles, laws lag behind.”
“For companies looking to think through a homogenous AI workflow or business plan, it’s very difficult, because you’re looking at each of the states that have implemented AI legislation, and trying to figure out a single, cohesive path,” Maguregui explained.
“I hope that a federal framework comes fast, but I don’t see it happening. And even if it does come, it’s going to take time to mature,” he continued.
As some pharmaceutical companies launch direct-to-consumer platforms with AI-led patient education, Maguregui pointed to examples of general principles companies need to keep in mind.
“The first one that I think is fairly common and obvious is just disclosure laws,” he said. “Are you using AI? Is AI being utilized during this consumer interaction?” Maguregui also noted some states require a human to remain in the AI loop, and others mandate platforms make clear to patients that AI is not a medical professional.
“On one hand, we want to emphasize innovation and pushing the needle in terms of technology and how helpful AI could be,” Maguregui added, emphasizing that understanding how these AI tools work, as well as their safety and quality, are also critical.
Aaron’s commentary also appeared in in Yahoo Finance.
